ANAXOMICS BIOTECH SL

Their core work

Anaxomics is a Barcelona-based computational biology SME specializing in systems biology and network medicine. They use mathematical modeling of biological networks to identify biomarkers, predict drug mechanisms of action, and support personalized medicine strategies across multiple disease areas. Their core service is translating complex omics data into actionable insights for pharmaceutical and clinical research teams, covering oncology, metabolic disease, neurodegeneration, and infectious disease. They consistently serve as the computational/bioinformatics partner within large EU research consortia.

What they specialise in

How they've shifted over time

In their early H2020 period (2017–2018), Anaxomics focused on liver disease (cirrhosis mechanisms), autophagy research, autoimmune disorders (rheumatoid arthritis, B-cell neoplasia), and foundational systems medicine approaches. From 2019 onward, their work shifted decisively toward cancer systems biology (tumor microenvironment, prostate cancer, gastric cancer), biomarker-driven personalized medicine, and multi-omics data integration. The trend shows a company moving from general disease modeling toward more targeted, translational applications where computational predictions directly inform clinical decisions.

Anaxomics is deepening its computational oncology and multi-omics capabilities, positioning itself as a go-to SME partner for precision medicine consortia that need network-based disease modeling.

How they like to work

Anaxomics operates exclusively as a consortium partner — they have never coordinated an H2020 project, instead contributing specialized computational expertise to large, multi-country consortia. With 174 unique partners across 30 countries in just 12 projects, they work in broad, diverse consortia rather than repeating with the same groups. This pattern suggests they are a sought-after specialist: different research teams independently recruit them for their systems biology capabilities, making them easy to integrate into new consortia.

Remarkably broad network for an SME: 174 unique consortium partners across 30 countries built through 12 projects. Their heavy participation in MSCA training networks (6 projects) gives them connections to universities and research institutes across nearly all of Europe.

What sets them apart

Anaxomics fills a specific niche that few SMEs occupy: they bring industrial-grade computational biology and network medicine to academic-led research consortia. Unlike university bioinformatics groups, they operate as a company with reproducible analytical pipelines and commercial accountability. Their disease-agnostic systems biology platform lets them contribute meaningfully to projects spanning cancer, neurodegeneration, metabolic disease, and infectious disease — making them an unusually versatile partner for any health-focused consortium needing computational modeling.

Highlights from their portfolio

• SMA-TB
  Their largest single grant (EUR 428,250) applying systems biology to predict tuberculosis treatment responses — an unusual pivot from their typical oncology and metabolic disease work.
• SECRET
  Directly addresses cancer therapy through the secretory pathway and tumor microenvironment, combining their core strengths in systems biology with targeted cancer treatment research.
• PROTrEIN
  Their most recent project (2021), focused on computational proteomics and multi-omics — signals the future direction of the company toward integrated data analysis platforms.